Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-Mel-PTCy vs Flu-Mel-ATG in Allogeneic Hematopoietic Cell Transplantation
NCT03852407Phase 2Recruiting
- Sponsor
- University of Liège
- Start
- Feb 2019
- Primary completion
- Nov 2033
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, antithymocyte globulin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), myeloproliferative neoplasm (MPN), acute lymphoblastic leukemia (ALL), sponsored by University of Liège. Started Feb 2019; status: recruiting.
02
Drugs
cyclophosphamideantithymocyte globulin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)myeloproliferative neoplasm (MPN)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03852407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852407.